SLATE Trademark

Trademark Overview

On Monday, July 9, 2018, a trademark application was filed for SLATE with the United States Patent and Trademark Office. The USPTO has given the SLATE trademark a serial number of 88030324. The federal status of this trademark filing is REGISTERED as of Tuesday, June 28, 2022. This trademark is owned by Gritstone Oncology, Inc.. The SLATE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Conducting evaluations in the field of pharmaceuticals; pharmaceutical product development and evaluation services; pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients
slate

General Information

Serial Number88030324
Word MarkSLATE
Filing DateMonday, July 9, 2018
Status700 - REGISTERED
Status DateTuesday, June 28, 2022
Registration Number6775121
Registration DateTuesday, June 28, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2019

Trademark Statements

Goods and ServicesConducting evaluations in the field of pharmaceuticals; pharmaceutical product development and evaluation services; pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, July 13, 2018
Primary Code042
First Use Anywhere DateSaturday, September 17, 2016
First Use In Commerce DateSaturday, September 17, 2016

Trademark Owner History

Party NameGRITSTONE BIO, INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressEmeryville, CA 94608
Party NameGRITSTONE BIO, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressEmeryville, CA 94608
Party NameGritstone Oncology, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressEmeryville, CA 94608
Party NameGritstone Oncology, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressEmeryville, CA 94608

Trademark Events

Event DateEvent Description
Tuesday, June 28, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, June 28, 2022REGISTERED-PRINCIPAL REGISTER
Saturday, May 21, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, May 20, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, May 20, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 20, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 20, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 1, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 1, 2022NON-FINAL ACTION E-MAILED
Friday, April 1, 2022SU - NON-FINAL ACTION - WRITTEN
Wednesday, March 2, 2022STATEMENT OF USE PROCESSING COMPLETE
Tuesday, February 8, 2022USE AMENDMENT FILED
Wednesday, March 2, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, February 8, 2022TEAS STATEMENT OF USE RECEIVED
Friday, August 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 18, 2021SOU EXTENSION 3 GRANTED
Wednesday, August 18, 2021SOU EXTENSION 3 FILED
Wednesday, August 18, 2021TEAS EXTENSION RECEIVED
Wednesday, June 23, 2021AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, February 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 16, 2021SOU EXTENSION 2 GRANTED
Tuesday, February 16, 2021SOU EXTENSION 2 FILED
Tuesday, February 16, 2021TEAS EXTENSION RECEIVED
Wednesday, August 5, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 5, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 5, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 23, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 21, 2020SOU EXTENSION 1 GRANTED
Tuesday, July 21, 2020SOU EXTENSION 1 FILED
Tuesday, July 21, 2020TEAS EXTENSION RECEIVED
Tuesday, February 18, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 24, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 24, 2019PUBLISHED FOR OPPOSITION
Wednesday, December 4, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 14, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 14, 2019SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Wednesday, November 13, 2019ASSIGNED TO LIE
Sunday, April 21, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, October 9, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, October 9, 2018LETTER OF SUSPENSION E-MAILED
Tuesday, October 9, 2018SUSPENSION LETTER WRITTEN
Friday, October 5, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 4, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 4, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 8, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 8, 2018NON-FINAL ACTION E-MAILED
Wednesday, August 8, 2018NON-FINAL ACTION WRITTEN
Tuesday, August 7, 2018ASSIGNED TO EXAMINER
Friday, July 13, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, July 12, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

slate research development cancer pharmaceutical field treatment data scientific namely pharmaceuticals